Literature DB >> 19151606

Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study.

Marcus Katoh1, Patrick Haage, Andrea J Wiethoff, Rolf W Günther, Arno Bücker, Josef Tacke, Elmar Spuentrup.   

Abstract

PURPOSE: To evaluate the value of a fibrin-specific MR contrast agent (EP-2104R; EPIX Pharmaceuticals) for detection of deep vein thrombosis (DVT) and monitoring of percutaneous intervention for treatment.
MATERIALS AND METHODS: In 6 domestic swine, DVT was induced in an iliac/femoral vein using an occlusion-balloon catheter and subsequent injection of thrombin. The occluded vessels were recanalized by mechanical thrombectomy using a Fogarty catheter and an Arrow rotating thrombectomy device. Magnetic resonance imaging of the pelvis and lung was repeated 4 times (before and after DVT induction, after contrast agent administration, and after intervention) using a 1.5-T whole-body XMR system (ACS-NT, Philips Medical Systems, Best, NL). The visualization of the thrombi and contrast-to-noise ratio (CNR) was assessed.
RESULTS: EP-2104R allowed selective visualization of thrombi with accurate determination of the extent of DVT with high contrast (CNR: 65.3 +/- 17.2). After intervention, dislodged thrombus fragments were selectively visualized in the lung (CNR: 27.9 +/- 9.3).
CONCLUSIONS: Molecular magnetic resonance imaging using fibrin-specific MR contrast agent EP-2104R allowed for selective visualization of DVT and monitoring of percutaneous intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151606     DOI: 10.1097/RLI.0b013e318195886d

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  12 in total

Review 1.  Cardiovascular molecular imaging: focus on clinical translation.

Authors:  Ian Y Chen; Joseph C Wu
Journal:  Circulation       Date:  2011-02-01       Impact factor: 29.690

Review 2.  Mechanisms of fibrin polymerization and clinical implications.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

3.  Molecular MRI of intracranial thrombus in a rat ischemic stroke model.

Authors:  Ritika Uppal; Ilknur Ay; Guangping Dai; Young Ro Kim; A Gregory Sorensen; Peter Caravan
Journal:  Stroke       Date:  2010-04-15       Impact factor: 7.914

4.  Radiolabelled probes for imaging of atherosclerotic plaques.

Authors:  Takashi Temma; Hideo Saji
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

5.  Molecular MRI of Thrombosis.

Authors:  Katie L Ciesienski; Peter Caravan
Journal:  Curr Cardiovasc Imaging Rep       Date:  2010

6.  High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity.

Authors:  Vincent Jacques; Stéphane Dumas; Wei-Chuan Sun; Jeffrey S Troughton; Matthew T Greenfield; Peter Caravan
Journal:  Invest Radiol       Date:  2010-10       Impact factor: 6.016

Review 7.  Animal models of venous thrombosis.

Authors:  Hassan Albadawi; Avery A Witting; Yash Pershad; Alex Wallace; Andrew R Fleck; Peter Hoang; Ali Khademhosseini; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 8.  Quantitative cardiovascular magnetic resonance for molecular imaging.

Authors:  Patrick M Winter; Shelton D Caruthers; Gregory M Lanza; Samuel A Wickline
Journal:  J Cardiovasc Magn Reson       Date:  2010-11-03       Impact factor: 5.364

9.  Molecular imaging of fibrin in a breast cancer xenograft mouse model.

Authors:  Ritika Uppal; Zdravka Medarova; Christian T Farrar; Guangping Dai; Anna Moore; Peter Caravan
Journal:  Invest Radiol       Date:  2012-10       Impact factor: 6.016

10.  Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis.

Authors:  Marcelo E Andia; Prakash Saha; Julia Jenkins; Bijan Modarai; Andrea J Wiethoff; Alkystis Phinikaridou; Steven P Grover; Ashish S Patel; Tobias Schaeffter; Alberto Smith; Rene M Botnar
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-04-10       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.